303 related articles for article (PubMed ID: 27899442)
1. Early generated B1 B cells with restricted BCRs become chronic lymphocytic leukemia with continued c-Myc and low Bmf expression.
Hayakawa K; Formica AM; Brill-Dashoff J; Shinton SA; Ichikawa D; Zhou Y; Morse HC; Hardy RR
J Exp Med; 2016 Dec; 213(13):3007-3024. PubMed ID: 27899442
[TBL] [Abstract][Full Text] [Related]
2. B cells generated by B-1 development can progress to chronic lymphocytic leukemia.
Hayakawa K; Formica AM; Colombo MJ; Ichikawa D; Shinton SA; Brill-Dashoff J; Hardy RR
Ann N Y Acad Sci; 2015 Dec; 1362():250-5. PubMed ID: 25907284
[TBL] [Abstract][Full Text] [Related]
3. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
4. Crucial Role of Increased Arid3a at the Pre-B and Immature B Cell Stages for B1a Cell Generation.
Hayakawa K; Li YS; Shinton SA; Bandi SR; Formica AM; Brill-Dashoff J; Hardy RR
Front Immunol; 2019; 10():457. PubMed ID: 30930899
[TBL] [Abstract][Full Text] [Related]
5. B-1 derived anti-Thy-1 B cells in old aged mice develop lymphoma/leukemia with high expression of CD11b and Hamp2 that different from TCL1 transgenic mice.
Hayakawa K; Zhou Y; Shinton SA
Immun Ageing; 2024 Apr; 21(1):22. PubMed ID: 38570827
[TBL] [Abstract][Full Text] [Related]
6. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.
Zhang W; Kater AP; Widhopf GF; Chuang HY; Enzler T; James DF; Poustovoitov M; Tseng PH; Janz S; Hoh C; Herschman H; Karin M; Kipps TJ
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18956-60. PubMed ID: 20956327
[TBL] [Abstract][Full Text] [Related]
7. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG
Blood; 2015 Mar; 125(10):1578-88. PubMed ID: 25564405
[TBL] [Abstract][Full Text] [Related]
8. Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.
Pal Singh S; de Bruijn MJW; de Almeida MP; Meijers RWJ; Nitschke L; Langerak AW; Pillai SY; Stadhouders R; Hendriks RW
Front Immunol; 2018; 9():1996. PubMed ID: 30271400
[TBL] [Abstract][Full Text] [Related]
9. CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progression.
Pede V; Rombout A; Vermeire J; Naessens E; Mestdagh P; Robberecht N; Vanderstraeten H; Van Roy N; Vandesompele J; Speleman F; Philippé J; Verhasselt B
PLoS One; 2013; 8(4):e60275. PubMed ID: 23560086
[TBL] [Abstract][Full Text] [Related]
10. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
[TBL] [Abstract][Full Text] [Related]
11. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia.
Alfarano A; Indraccolo S; Circosta P; Minuzzo S; Vallario A; Zamarchi R; Fregonese A; Calderazzo F; Faldella A; Aragno M; Camaschella C; Amadori A; Caligaris-Cappio F
Blood; 1999 Apr; 93(7):2327-35. PubMed ID: 10090943
[TBL] [Abstract][Full Text] [Related]
12. Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells.
Hayakawa K; Formica AM; Colombo MJ; Shinton SA; Brill-Dashoff J; Morse Iii HC; Li YS; Hardy RR
Leukemia; 2016 Jul; 30(7):1510-9. PubMed ID: 27055869
[TBL] [Abstract][Full Text] [Related]
13. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
[TBL] [Abstract][Full Text] [Related]
14. BCR engagement in CLL: when translation goes wrong.
Paggetti J; Moussay E
Blood; 2016 Jan; 127(4):378-80. PubMed ID: 26823509
[TBL] [Abstract][Full Text] [Related]
15. Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach.
Colombo M; Bagnara D; Reverberi D; Matis S; Cardillo M; Massara R; Mastracci L; Ravetti JL; Agnelli L; Neri A; Mazzocco M; Squillario M; Mazzarello AN; Cutrona G; Agathangelidis A; Stamatopoulos K; Ferrarini M; Fais F
Mol Med; 2020 Mar; 26(1):25. PubMed ID: 32156260
[TBL] [Abstract][Full Text] [Related]
16. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.
Röder B; Fahnenstiel H; Schäfer S; Budeus B; Dampmann M; Eichhorn M; Angermüller S; Brost C; Winkler TH; Seifert M; Nitschke L
EMBO Rep; 2023 Aug; 24(8):e56420. PubMed ID: 37424400
[TBL] [Abstract][Full Text] [Related]
18. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.
Tobin G; Thunberg U; Karlsson K; Murray F; Laurell A; Willander K; Enblad G; Merup M; Vilpo J; Juliusson G; Sundström C; Söderberg O; Roos G; Rosenquist R
Blood; 2004 Nov; 104(9):2879-85. PubMed ID: 15217826
[TBL] [Abstract][Full Text] [Related]
19. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
Ten Hacken E; Gounari M; Ghia P; Burger JA
Leukemia; 2019 Feb; 33(2):287-298. PubMed ID: 30555163
[TBL] [Abstract][Full Text] [Related]
20. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
